GESTAÇÃO E PUERPÉRIO EM TEMPOS DE COVID-19: ASPECTOS CLÍNICOS E MANEJO TERAPÊUTICO

The infection caused by the new coronavirus, has high transmissibility which has reached many countries becoming a state of emergency in public health worldwide. Postpartum women and pregnant women are part of the risk group, as their physiological state is constantly adaptively and mechanically changing, becoming more susceptible to infections. This study aimed to elucidate the therapeutic management and the clinical aspects in pregnant and postpartum women against Covid-19. This is a narrative review study that seeks to elucidate the critical view on the given subject. The National Center For Biotechnology Information (PubMed) scientific database was used. It was found that most of the articles included in the research contained clinical information about the pregnant women, but little information about the puerperal women. The use of some non-retroviral antivirals did not show teratogenic effects to the fetus, which showed a reduction in viral load. The clinical aspects of this group included odynophagia, anosmia, fever, among others, with an extension of symptom improvement when compared to non-pregnant women. It presented the increase of the incidence of susceptibility to infections and the rate of abnormal liver transaminases. Pregnant women usually represent a unique group and are vulnerable to infectious diseases, so it is very important to include them in the Covid-19 risk group. In general, there is no specific and effective drug for the treatment of Covid-19 during pregnancy, however, Chloroquine, Lopinavir, Ritonavir or Interferon-alpha are mentioned and have shown positive results in the treatment of Covid-19 in pregnant women.